Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2016 | 1 |
2018 | 1 |
2023 | 1 |
2024 | 2 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Conflict of Interest Disclosures.
Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597.
Global Spine J. 2023.
PMID: 37222100
Free PMC article.
No abstract available.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators.
Dimopoulos MA, et al.
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
Lancet Oncol. 2016.
PMID: 26671818
Free article.
Clinical Trial.
Patients received treatment until progression with carfilzomib (20 mg/m(2) on days 1 and 2 of cycle 1; 56 mg/m(2) thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1.3 mg/m(2); intravenous bolus or …
Patients received treatment until progression with carfilzomib (20 mg/m(2) on days 1 and 2 of cycle 1; 56 mg/m(2) thereafter; …
Item in Clipboard
Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Fertility and Forecasting Collaborators.
GBD 2021 Fertility and Forecasting Collaborators.
Lancet. 2024 Mar 19:S0140-6736(24)00550-6. doi: 10.1016/S0140-6736(24)00550-6. Online ahead of print.
Lancet. 2024.
PMID: 38521087
Free article.
Item in Clipboard
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Causes of Death Collaborators.
GBD 2021 Causes of Death Collaborators.
Lancet. 2024 Apr 3:S0140-6736(24)00367-2. doi: 10.1016/S0140-6736(24)00367-2. Online ahead of print.
Lancet. 2024.
PMID: 38582094
Free article.
Item in Clipboard
Comparison Of Hospitals Participating In Medicare's Voluntary And Mandatory Orthopedic Bundle Programs.
Navathe AS, Liao JM, Polsky D, Shah Y, Huang Q, Zhu J, Lyon ZM, Wang R, Rolnick J, Martinez JR, Emanuel EJ.
Navathe AS, et al.
Health Aff (Millwood). 2018 Jun;37(6):854-863. doi: 10.1377/hlthaff.2017.1358.
Health Aff (Millwood). 2018.
PMID: 29863929
Free PMC article.
Item in Clipboard
Cite
Cite